Dietary chemoprevention of PhIP induced carcinogenesis in male Fischer 344 rats with tomato and broccoli.

PubWeight™: 0.78‹?›

🔗 View Article (PMC 3842290)

Published in PLoS One on November 27, 2013

Authors

Kirstie Canene-Adams1, Karen S Sfanos, Chung-Tiang Liang, Srinivasan Yegnasubramanian, William G Nelson, Cory Brayton, Angelo M De Marzo

Author Affiliations

1: Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America.

Articles cited by this

Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr Cancer (1992) 6.12

Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol (1999) 4.85

Vegetables, fruit, and cancer prevention: a review. J Am Diet Assoc (1996) 4.62

Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst (1995) 3.24

Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A (1994) 3.24

A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst (2002) 2.49

An evaluation of the Dietary Guidelines for Americans in relation to cancer occurrence. Am J Clin Nutr (2002) 2.04

A prospective study of cruciferous vegetables and prostate cancer. Cancer Epidemiol Biomarkers Prev (2003) 2.04

Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer (1989) 1.91

The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol Biomarkers Prev (2004) 1.65

A prospective study of meat and meat mutagens and prostate cancer risk. Cancer Res (2005) 1.63

GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol (2001) 1.60

The prostate: a target for carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) derived from cooked foods. Cancer Res (1997) 1.57

Brassica vegetables and prostate cancer risk: a review of the epidemiological evidence. Nutr Cancer (2002) 1.46

Cancer incidence among Korean-American immigrants in the United States and native Koreans in South Korea. Cancer Control (2007) 1.45

p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology (2001) 1.44

A case-control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese diet. Cancer Sci (2004) 1.44

Relationships between organ weight and body/brain weight in the rat: what is the best analytical endpoint? Toxicol Pathol (2004) 1.41

Meat consumption among Black and White men and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev (2006) 1.34

Adherence to the AICR cancer prevention recommendations and subsequent morbidity and mortality in the Iowa Women's Health Study cohort. Cancer Epidemiol Biomarkers Prev (2004) 1.28

Factors contributing to the racial differences in prostate cancer mortality. BJU Int (2005) 1.26

Combinations of tomato and broccoli enhance antitumor activity in dunning r3327-h prostate adenocarcinomas. Cancer Res (2007) 1.26

The dietary charred meat carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine acts as both a tumor initiator and promoter in the rat ventral prostate. Cancer Res (2007) 1.23

Protection against 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine cytotoxicity and DNA adduct formation in human prostate by glutathione S-transferase P1. Cancer Res (2001) 1.22

Meat mutagens and risk of distal colon adenoma in a cohort of U.S. men. Cancer Epidemiol Biomarkers Prev (2006) 1.17

Estimates of heterocyclic amine intake in the US population. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 1.14

Inflammation and atrophy precede prostatic neoplasia in a PhIP-induced rat model. Neoplasia (2006) 1.11

The relationship between the consumption of meat, fat, and coffee and the risk of colon cancer: a prospective study in Japan. Cancer Lett (2006) 1.09

Ethnic group-related differences in CpG hypermethylation of the GSTP1 gene promoter among African-American, Caucasian and Asian patients with prostate cancer. Int J Cancer (2005) 1.06

Diet and cancer. Acta Biomed (2006) 1.03

Carcinogenicity of 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP) in the rat prostate and induction of invasive carcinomas by subsequent treatment with testosterone propionate. Cancer Lett (1999) 1.02

Modeling human colon cancer in rodents using a food-borne carcinogen, PhIP. Cancer Sci (2005) 1.02

Expression of cytochromes P450 and glutathione S-transferases in human prostate, and the potential for activation of heterocyclic amine carcinogens via acetyl-coA-, PAPS- and ATP-dependent pathways. Int J Cancer (2005) 1.01

Meat consumption, cooking practices, meat mutagens, and risk of prostate cancer. Nutr Cancer (2011) 1.01

GSTA1 expression in normal, preneoplastic, and neoplastic human prostate tissue. Prostate (2001) 1.00

Molecular and genetic toxicology of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Mutat Res (2002) 0.98

Protective versus promotional effects of white tea and caffeine on PhIP-induced tumorigenesis and beta-catenin expression in the rat. Carcinogenesis (2008) 0.97

Highly elevated PSA and dietary PhIP intake in a prospective clinic-based study among African Americans. Prostate Cancer Prostatic Dis (2007) 0.96

Dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced prostate carcinogenesis in CYP1A-humanized mice. Cancer Prev Res (Phila) (2012) 0.93

Prostate mutations in rats induced by the suspected human carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Res (2000) 0.92

High susceptibility of the ACI and spontaneously hypertensive rat (SHR) strains to 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) prostate carcinogenesis. Cancer Sci (2003) 0.91

Effects of arctiin on PhIP-induced mammary, colon and pancreatic carcinogenesis in female Sprague-Dawley rats and MeIQx-induced hepatocarcinogenesis in male F344 rats. Cancer Lett (2000) 0.91

Development of the 2010 US Dietary Guidelines Advisory Committee Report: perspectives from a registered dietitian. J Am Diet Assoc (2010) 0.90

Dose-dependence of 2-amino-1-methyl-6-phenylimidazo[4,5-b]-pyridine (PhIP) carcinogenicity in rats. Carcinogenesis (1993) 0.89

Tomatoes, lycopene, and prostate cancer. Proc Soc Exp Biol Med (1998) 0.89

Potential sources of carcinogenic heterocyclic amines in the Chinese diet: results from a 24-h dietary recall study in Singapore. Eur J Clin Nutr (2005) 0.87

Dietary exposure to heterocyclic amines in a Chinese population. Nutr Cancer (2005) 0.86

Inhibitory effects of soy isoflavones on rat prostate carcinogenesis induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Carcinogenesis (2003) 0.85

Organ differences in the enhancing potential of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine on carcinogenicity in the prostate, colon and pancreas. Mutat Res (2002) 0.82

Human sensitivity to PhIP: a novel marker for prostate cancer risk. Mutat Res (2006) 0.82

Humanizing π-class glutathione S-transferase regulation in a mouse model alters liver toxicity in response to acetaminophen overdose. PLoS One (2011) 0.81

Beta-carotene did not work: aftermath of the ATBC study. Cancer Lett (1997) 0.80

Beta carotene fails to prevent cancer in two major studies; CARET intervention stopped. J Natl Cancer Inst (1996) 0.77

Equivocal impact of transplacental and lactational exposure to a food-derived carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, on prostate and colon lesion development in F344 rats. Cancer Lett (2004) 0.76

Articles by these authors

c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature (2009) 13.28

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29

p53 mutant mice that display early ageing-associated phenotypes. Nature (2002) 10.05

Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08

Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61

TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (2007) 6.09

Prostate cancer. N Engl J Med (2003) 5.91

Tracking the clonal origin of lethal prostate cancer. J Clin Invest (2013) 5.79

Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood (2002) 4.88

Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res (2012) 4.67

Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21

Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83

Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res (2008) 3.67

Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 3.29

Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol (2008) 3.18

Pathological and molecular aspects of prostate cancer. Lancet (2003) 2.98

Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res (2004) 2.84

Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res (2002) 2.84

Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget (2011) 2.80

A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer Discov (2011) 2.77

Epidemiology of inflammation and prostate cancer. J Urol (2004) 2.76

Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res (2002) 2.71

Prostate cancer and inflammation: the evidence. Histopathology (2012) 2.60

Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol (2002) 2.44

Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41

miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res (2009) 2.39

Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell (2005) 2.37

Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. J Clin Endocrinol Metab (2007) 2.36

PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res (2011) 2.35

Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis (2004) 2.33

Moderate reduction of gamma-secretase attenuates amyloid burden and limits mechanism-based liabilities. J Neurosci (2007) 2.31

The role of inflammation in the pathogenesis of prostate cancer. J Urol (2004) 2.29

Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res (2002) 2.24

Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24

NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw (2011) 2.24

Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther (2010) 2.21

Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol (2007) 2.20

Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate (2009) 2.17

Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab (2003) 2.16

Accurate genome-scale percentage DNA methylation estimates from microarray data. Biostatistics (2010) 2.11

DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res (2008) 2.08

Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care (2007) 2.08

A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. Prostate (2008) 2.04

Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2006) 2.00

Telomere length assessment in human archival tissues: combined telomere fluorescence in situ hybridization and immunostaining. Am J Pathol (2002) 1.95

XMRV: a new virus in prostate cancer? Cancer Res (2010) 1.95

A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res (2012) 1.92

p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells. Cancer Biol Ther (2004) 1.90

Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines. Cancer Biol Ther (2003) 1.88

Procainamide is a specific inhibitor of DNA methyltransferase 1. J Biol Chem (2005) 1.84

MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine. Cancer Biol Ther (2004) 1.82

Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer. J Biol Chem (2005) 1.79

Gleason score 6 adenocarcinoma: should it be labeled as cancer? J Clin Oncol (2012) 1.78

Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol (2011) 1.76

Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. Cancer Res (2006) 1.76

Cyclooxygenases in cancer: progress and perspective. Cancer Lett (2004) 1.74

Methyl-CpG binding domain protein 2 represses transcription from hypermethylated pi-class glutathione S-transferase gene promoters in hepatocellular carcinoma cells. J Biol Chem (2002) 1.72

Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol (2009) 1.71

Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res (2007) 1.71

Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am J Pathol (2003) 1.67

Loss-of-function of Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis. Cancer Res (2005) 1.66

Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am J Pathol (2003) 1.65

MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS One (2010) 1.65

DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med (2013) 1.63

Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2014) 1.61

Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells. Proc Natl Acad Sci U S A (2006) 1.61

Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev (2004) 1.60

Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Mol Cancer Res (2008) 1.59

A novel role of myosin VI in human prostate cancer. Am J Pathol (2006) 1.59

Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol (2011) 1.58

GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem (2004) 1.58

Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial. Int J Cancer (2009) 1.56

Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. J Cell Biochem (2004) 1.56

Epigenetic alterations in human prostate cancers. Endocrinology (2009) 1.55